| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 83 | 2024 | 1427 | 3.710 |
Why?
|
| Prostatectomy | 24 | 2024 | 313 | 1.230 |
Why?
|
| Genetic Therapy | 18 | 2011 | 725 | 1.190 |
Why?
|
| Prostate-Specific Antigen | 13 | 2008 | 236 | 1.040 |
Why?
|
| Prostate | 21 | 2017 | 415 | 0.810 |
Why?
|
| Thymidine Kinase | 10 | 2006 | 89 | 0.600 |
Why?
|
| Caveolin 1 | 6 | 2009 | 51 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 4 | 2011 | 406 | 0.410 |
Why?
|
| Biomarkers, Tumor | 10 | 2013 | 1624 | 0.380 |
Why?
|
| Genetic Vectors | 12 | 2011 | 908 | 0.360 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 12 | 0.360 |
Why?
|
| Adenoviridae | 11 | 2011 | 585 | 0.350 |
Why?
|
| Putrescine | 8 | 1990 | 11 | 0.340 |
Why?
|
| Ganciclovir | 7 | 2006 | 102 | 0.340 |
Why?
|
| Antineoplastic Agents | 9 | 2008 | 1811 | 0.310 |
Why?
|
| Male | 100 | 2024 | 65464 | 0.310 |
Why?
|
| Adenocarcinoma | 8 | 2005 | 1006 | 0.310 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 1130 | 0.300 |
Why?
|
| Boronic Acids | 1 | 2008 | 49 | 0.280 |
Why?
|
| Pyrazines | 1 | 2008 | 79 | 0.280 |
Why?
|
| Fenretinide | 4 | 2000 | 9 | 0.270 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 224 | 0.270 |
Why?
|
| Lymph Node Excision | 4 | 2024 | 171 | 0.260 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 679 | 0.260 |
Why?
|
| Aged | 37 | 2013 | 21279 | 0.260 |
Why?
|
| Simplexvirus | 8 | 2006 | 100 | 0.250 |
Why?
|
| Carcinoma | 3 | 2017 | 284 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2008 | 482 | 0.250 |
Why?
|
| Middle Aged | 39 | 2017 | 28939 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2010 | 1282 | 0.240 |
Why?
|
| Antiviral Agents | 8 | 2006 | 813 | 0.230 |
Why?
|
| Aircraft | 1 | 2005 | 22 | 0.230 |
Why?
|
| Trans-Activators | 1 | 2008 | 692 | 0.220 |
Why?
|
| Occupational Diseases | 1 | 2005 | 79 | 0.220 |
Why?
|
| Lymphocele | 1 | 2024 | 5 | 0.210 |
Why?
|
| Prostatic Hyperplasia | 8 | 2004 | 119 | 0.210 |
Why?
|
| Pelvis | 2 | 2024 | 70 | 0.200 |
Why?
|
| Sural Nerve | 4 | 2007 | 46 | 0.200 |
Why?
|
| Eflornithine | 8 | 1992 | 15 | 0.190 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 234 | 0.190 |
Why?
|
| Anticholesteremic Agents | 1 | 2005 | 241 | 0.190 |
Why?
|
| Genes, ras | 9 | 1998 | 99 | 0.190 |
Why?
|
| Combined Modality Therapy | 9 | 2007 | 1261 | 0.190 |
Why?
|
| Humans | 77 | 2024 | 132158 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 10 | 1996 | 463 | 0.170 |
Why?
|
| Biopsy, Needle | 4 | 2007 | 216 | 0.170 |
Why?
|
| Stromal Cells | 4 | 2017 | 314 | 0.170 |
Why?
|
| Membrane Proteins | 3 | 2013 | 1617 | 0.170 |
Why?
|
| Penile Erection | 5 | 2007 | 80 | 0.170 |
Why?
|
| Isotretinoin | 1 | 2000 | 19 | 0.170 |
Why?
|
| Vitamin A | 1 | 2000 | 57 | 0.160 |
Why?
|
| Tretinoin | 1 | 2000 | 97 | 0.160 |
Why?
|
| Genes, myc | 9 | 1995 | 95 | 0.160 |
Why?
|
| Lung Neoplasms | 9 | 2007 | 1552 | 0.160 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2000 | 76 | 0.160 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 236 | 0.150 |
Why?
|
| Neurogenesis | 2 | 2013 | 222 | 0.150 |
Why?
|
| Denervation | 2 | 2017 | 26 | 0.150 |
Why?
|
| Immunotherapy | 4 | 2013 | 760 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 646 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 747 | 0.140 |
Why?
|
| Ornithine | 5 | 1985 | 33 | 0.140 |
Why?
|
| Prostatic Diseases | 2 | 1989 | 14 | 0.140 |
Why?
|
| Interleukin-12 | 2 | 2008 | 124 | 0.130 |
Why?
|
| Pons | 1 | 1996 | 34 | 0.120 |
Why?
|
| Parietal Lobe | 1 | 1996 | 47 | 0.120 |
Why?
|
| Aged, 80 and over | 11 | 2013 | 6924 | 0.120 |
Why?
|
| Follow-Up Studies | 10 | 2006 | 5283 | 0.120 |
Why?
|
| Semaphorins | 2 | 2013 | 35 | 0.120 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2017 | 126 | 0.120 |
Why?
|
| Acyclovir | 3 | 2004 | 47 | 0.120 |
Why?
|
| Animals | 44 | 2017 | 34288 | 0.110 |
Why?
|
| Valine | 3 | 2004 | 110 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2004 | 462 | 0.110 |
Why?
|
| Apoptosis | 5 | 2013 | 1863 | 0.110 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 1140 | 0.110 |
Why?
|
| Finasteride | 3 | 2002 | 16 | 0.110 |
Why?
|
| Cysts | 2 | 2000 | 93 | 0.110 |
Why?
|
| Tuberculosis, Renal | 1 | 1994 | 3 | 0.110 |
Why?
|
| Kidney Pelvis | 1 | 1994 | 44 | 0.100 |
Why?
|
| Neuroepithelial Cells | 1 | 2013 | 8 | 0.100 |
Why?
|
| Seminal Vesicles | 2 | 2013 | 52 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 1226 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2006 | 66 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 1996 | 321 | 0.100 |
Why?
|
| Time Factors | 7 | 2006 | 6288 | 0.100 |
Why?
|
| Caveolins | 2 | 2003 | 14 | 0.100 |
Why?
|
| Tomography, Emission-Computed | 2 | 1990 | 36 | 0.100 |
Why?
|
| Cancer Vaccines | 2 | 2013 | 191 | 0.100 |
Why?
|
| Adult | 13 | 2008 | 31755 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2005 | 632 | 0.090 |
Why?
|
| Kidney Neoplasms | 3 | 2000 | 454 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1994 | 181 | 0.090 |
Why?
|
| Neoplasm Metastasis | 8 | 2003 | 710 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 234 | 0.090 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2013 | 100 | 0.090 |
Why?
|
| Mice | 24 | 2017 | 18397 | 0.090 |
Why?
|
| Erectile Dysfunction | 3 | 2005 | 197 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2010 | 1333 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2017 | 241 | 0.090 |
Why?
|
| Biopsy | 5 | 2017 | 1252 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2013 | 2031 | 0.090 |
Why?
|
| BCG Vaccine | 2 | 1991 | 110 | 0.090 |
Why?
|
| Chromogranins | 1 | 1991 | 30 | 0.090 |
Why?
|
| Reference Values | 3 | 2005 | 693 | 0.090 |
Why?
|
| Carbon Radioisotopes | 4 | 1989 | 68 | 0.080 |
Why?
|
| Macrophages | 2 | 2008 | 664 | 0.080 |
Why?
|
| NF-kappa B | 2 | 2013 | 451 | 0.080 |
Why?
|
| Androgens | 4 | 1992 | 272 | 0.080 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 4692 | 0.080 |
Why?
|
| Mesoderm | 4 | 1995 | 108 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2000 | 2462 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 402 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2010 | 5124 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 1991 | 546 | 0.080 |
Why?
|
| Diethylstilbestrol | 3 | 1985 | 42 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 343 | 0.080 |
Why?
|
| Rats | 14 | 1990 | 3459 | 0.080 |
Why?
|
| Razoxane | 4 | 1982 | 9 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 725 | 0.080 |
Why?
|
| Risk | 1 | 2011 | 739 | 0.080 |
Why?
|
| Dihydrotestosterone | 3 | 1989 | 72 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2007 | 453 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 1614 | 0.070 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 31 | 0.070 |
Why?
|
| Bortezomib | 1 | 2008 | 72 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2007 | 256 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 3714 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 589 | 0.070 |
Why?
|
| Piperazines | 4 | 2001 | 273 | 0.070 |
Why?
|
| Survival Rate | 3 | 2007 | 2154 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2008 | 257 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 1996 | 1307 | 0.060 |
Why?
|
| Rats, Inbred Strains | 8 | 1989 | 199 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 2 | 2000 | 46 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 495 | 0.060 |
Why?
|
| Penis | 1 | 2007 | 97 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2008 | 1019 | 0.060 |
Why?
|
| Immunity, Cellular | 2 | 2005 | 193 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1986 | 92 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 27 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2008 | 777 | 0.060 |
Why?
|
| Prognosis | 4 | 2010 | 4965 | 0.060 |
Why?
|
| F-Box Proteins | 1 | 2006 | 32 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 244 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 85 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 359 | 0.060 |
Why?
|
| Disease Progression | 4 | 2017 | 2230 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2013 | 2488 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 11 | 2002 | 4734 | 0.060 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2005 | 48 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2024 | 13017 | 0.060 |
Why?
|
| Abscess | 1 | 1986 | 139 | 0.060 |
Why?
|
| Gene Expression | 2 | 2007 | 1508 | 0.060 |
Why?
|
| Double-Blind Method | 5 | 2002 | 1638 | 0.050 |
Why?
|
| Ultrasonography | 1 | 1989 | 979 | 0.050 |
Why?
|
| Escherichia coli Infections | 1 | 1986 | 196 | 0.050 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 51 | 0.050 |
Why?
|
| Mental Recall | 1 | 2005 | 142 | 0.050 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2003 | 3 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 136 | 0.050 |
Why?
|
| Urinary Calculi | 1 | 2003 | 19 | 0.050 |
Why?
|
| Transfection | 4 | 2013 | 960 | 0.050 |
Why?
|
| Polyamines | 3 | 1992 | 37 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2006 | 364 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 345 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 307 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 703 | 0.050 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2002 | 14 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2000 | 237 | 0.050 |
Why?
|
| Retroviridae | 2 | 2007 | 182 | 0.050 |
Why?
|
| Lipids | 1 | 2005 | 566 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 705 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 203 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1350 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 602 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2006 | 17763 | 0.040 |
Why?
|
| Neoplasms, Experimental | 6 | 1991 | 205 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2005 | 1476 | 0.040 |
Why?
|
| Defective Viruses | 1 | 2000 | 17 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 1993 | 610 | 0.040 |
Why?
|
| Neoplasms, Mesothelial | 1 | 2000 | 1 | 0.040 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 4 | 1992 | 10 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 44 | 0.040 |
Why?
|
| Placebos | 1 | 2000 | 227 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 390 | 0.040 |
Why?
|
| Tissue Distribution | 4 | 1990 | 367 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2000 | 31 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2024 | 6544 | 0.040 |
Why?
|
| Necrosis | 1 | 2000 | 195 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2000 | 126 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2001 | 237 | 0.040 |
Why?
|
| Bone Density | 1 | 2002 | 362 | 0.040 |
Why?
|
| Prodrugs | 3 | 2004 | 56 | 0.040 |
Why?
|
| Neoplasm Transplantation | 4 | 2001 | 361 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 452 | 0.040 |
Why?
|
| Genes, p53 | 2 | 1998 | 213 | 0.030 |
Why?
|
| Penile Neoplasms | 1 | 1998 | 37 | 0.030 |
Why?
|
| Calcium | 1 | 2003 | 1039 | 0.030 |
Why?
|
| Predictive Value of Tests | 4 | 2007 | 2323 | 0.030 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2017 | 17 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2000 | 573 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 882 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 986 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1998 | 179 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 910 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 2004 | 2144 | 0.030 |
Why?
|
| Kidney | 1 | 2003 | 1304 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 277 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1976 | 62 | 0.030 |
Why?
|
| Epithelium | 5 | 1995 | 344 | 0.030 |
Why?
|
| Hemangioma | 1 | 1976 | 92 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2005 | 3134 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 126 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 2994 | 0.030 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 1706 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2008 | 530 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 1994 | 2585 | 0.030 |
Why?
|
| Coitus | 2 | 2005 | 22 | 0.030 |
Why?
|
| Radioimmunoassay | 2 | 1991 | 85 | 0.030 |
Why?
|
| Flutamide | 2 | 2004 | 26 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 72 | 0.020 |
Why?
|
| Leuprolide | 2 | 2004 | 23 | 0.020 |
Why?
|
| Injections, Intralesional | 2 | 2005 | 46 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 4 | 2001 | 985 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2004 | 221 | 0.020 |
Why?
|
| Base Sequence | 4 | 2001 | 2784 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2017 | 795 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1998 | 761 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 115 | 0.020 |
Why?
|
| ROC Curve | 2 | 2004 | 623 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1230 | 0.020 |
Why?
|
| Chromogranin A | 1 | 1991 | 4 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2013 | 226 | 0.020 |
Why?
|
| DNA Primers | 2 | 2003 | 609 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2000 | 1916 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2003 | 1488 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 1990 | 12 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 494 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1982 | 440 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 1986 | 120 | 0.020 |
Why?
|
| Phenotype | 2 | 2017 | 4550 | 0.020 |
Why?
|
| Mutation | 2 | 2006 | 6206 | 0.020 |
Why?
|
| Genital Diseases, Male | 1 | 1989 | 13 | 0.020 |
Why?
|
| Cell Line | 6 | 1995 | 2591 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1990 | 261 | 0.020 |
Why?
|
| Gelatin | 1 | 2008 | 17 | 0.020 |
Why?
|
| Mullerian Ducts | 1 | 1989 | 47 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2008 | 41 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 89 | 0.020 |
Why?
|
| Hemostatics | 1 | 2008 | 58 | 0.020 |
Why?
|
| Castration | 2 | 1991 | 31 | 0.020 |
Why?
|
| Clathrin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Caveolae | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cell Division | 3 | 2000 | 720 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 60 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 62 | 0.020 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2007 | 34 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 67 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 1993 | 2367 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 2005 | 1173 | 0.020 |
Why?
|
| Premedication | 1 | 1986 | 39 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 831 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1986 | 7 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 281 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 849 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 713 | 0.020 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2006 | 20 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 382 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1235 | 0.010 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 53 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2007 | 4078 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 1996 | 3532 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 283 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1976 | 1408 | 0.010 |
Why?
|
| Ornithine Decarboxylase | 2 | 1982 | 18 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2005 | 42 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1986 | 260 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 121 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 344 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 243 | 0.010 |
Why?
|
| Catheterization | 1 | 1986 | 234 | 0.010 |
Why?
|
| Libido | 1 | 2005 | 34 | 0.010 |
Why?
|
| Drainage | 1 | 1986 | 252 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 512 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2004 | 30 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 1320 | 0.010 |
Why?
|
| Mitoguazone | 1 | 1984 | 3 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2004 | 88 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 216 | 0.010 |
Why?
|
| Guanidines | 1 | 1984 | 21 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 208 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1984 | 116 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1985 | 330 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2005 | 335 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2004 | 114 | 0.010 |
Why?
|
| Nephrectomy | 2 | 2000 | 175 | 0.010 |
Why?
|
| Recurrence | 1 | 2007 | 1484 | 0.010 |
Why?
|
| Morphogenesis | 2 | 1995 | 199 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 2003 | 171 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 1982 | 16 | 0.010 |
Why?
|
| Cell Communication | 2 | 1995 | 190 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1982 | 13 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1982 | 13 | 0.010 |
Why?
|
| Lymphatic Metastasis | 2 | 1981 | 433 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1982 | 64 | 0.010 |
Why?
|
| Nucleoside Deaminases | 1 | 2002 | 23 | 0.010 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 15 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 2002 | 15 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 696 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1984 | 542 | 0.010 |
Why?
|
| Orchiectomy | 2 | 1992 | 52 | 0.010 |
Why?
|
| Algorithms | 1 | 1989 | 1690 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 511 | 0.010 |
Why?
|
| Lymphatic Irradiation | 1 | 2001 | 4 | 0.010 |
Why?
|
| Carboxy-Lyases | 1 | 1982 | 16 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2002 | 70 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 796 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 323 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2002 | 199 | 0.010 |
Why?
|
| Biomarkers | 1 | 1991 | 3426 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 459 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 227 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 402 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1991 | 236 | 0.010 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 57 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1982 | 301 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 337 | 0.010 |
Why?
|
| Sulfones | 1 | 2001 | 73 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 54 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 769 | 0.010 |
Why?
|
| Purines | 1 | 2001 | 115 | 0.010 |
Why?
|
| Nerve Regeneration | 1 | 2001 | 76 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1980 | 28 | 0.010 |
Why?
|
| Diet | 2 | 2000 | 1119 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2000 | 114 | 0.010 |
Why?
|
| Receptors, Androgen | 2 | 1994 | 419 | 0.010 |
Why?
|
| RNA | 2 | 1995 | 530 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2001 | 206 | 0.010 |
Why?
|
| Heparin | 1 | 1980 | 206 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2001 | 303 | 0.010 |
Why?
|
| Keratins | 1 | 1998 | 51 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1986 | 2128 | 0.010 |
Why?
|
| Bacteria | 1 | 2002 | 537 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1978 | 69 | 0.010 |
Why?
|
| Pain | 1 | 2000 | 439 | 0.010 |
Why?
|
| Virus Replication | 1 | 2000 | 599 | 0.010 |
Why?
|
| Kinetics | 2 | 1992 | 1093 | 0.010 |
Why?
|
| Risk Factors | 1 | 1991 | 11034 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1998 | 451 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2000 | 506 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 3096 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 121 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 738 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 3864 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2001 | 3458 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 2117 | 0.010 |
Why?
|
| Lung | 1 | 2001 | 1580 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 121 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 4699 | 0.010 |
Why?
|
| Genes, jun | 1 | 1992 | 7 | 0.010 |
Why?
|
| Genes, fos | 1 | 1992 | 14 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1992 | 36 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1992 | 32 | 0.010 |
Why?
|
| Female | 5 | 2001 | 71430 | 0.010 |
Why?
|
| Cell Death | 1 | 1992 | 237 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 126 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1993 | 230 | 0.010 |
Why?
|
| Clone Cells | 1 | 1992 | 158 | 0.010 |
Why?
|
| Oncogenes | 1 | 1992 | 164 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1992 | 115 | 0.010 |
Why?
|
| Alleles | 1 | 1995 | 1709 | 0.000 |
Why?
|
| Fetus | 1 | 1993 | 585 | 0.000 |
Why?
|
| Promoter Regions, Genetic | 1 | 1993 | 1221 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1986 | 27 | 0.000 |
Why?
|
| Neurons | 1 | 1996 | 2009 | 0.000 |
Why?
|
| Fluorine | 1 | 1986 | 12 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1993 | 1950 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1984 | 53 | 0.000 |
Why?
|
| Spermidine | 1 | 1984 | 5 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1984 | 239 | 0.000 |
Why?
|
| Progesterone | 1 | 1986 | 446 | 0.000 |
Why?
|
| Radiography | 1 | 1986 | 761 | 0.000 |
Why?
|
| Biological Transport | 1 | 1984 | 333 | 0.000 |
Why?
|
| Transfer Factor | 1 | 1982 | 1 | 0.000 |
Why?
|
| Levamisole | 1 | 1982 | 4 | 0.000 |
Why?
|
| Picibanil | 1 | 1982 | 4 | 0.000 |
Why?
|
| Hemocyanins | 1 | 1982 | 23 | 0.000 |
Why?
|
| Poly I-C | 1 | 1982 | 22 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1982 | 217 | 0.000 |
Why?
|
| Random Allocation | 1 | 1982 | 423 | 0.000 |
Why?
|
| Interferons | 1 | 1982 | 136 | 0.000 |
Why?
|
| Thymidine | 1 | 1981 | 49 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1982 | 287 | 0.000 |
Why?
|
| Pregnancy | 1 | 1994 | 7603 | 0.000 |
Why?
|
| Lymph | 1 | 1980 | 7 | 0.000 |
Why?
|
| Thromboembolism | 1 | 1980 | 92 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1982 | 1171 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1984 | 985 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1984 | 2947 | 0.000 |
Why?
|
| DNA | 1 | 1982 | 1441 | 0.000 |
Why?
|